chrX-54449716-A-G

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_004463.3(FGD1):​c.2091T>C​(p.Thr697Thr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0507 in 1,206,541 control chromosomes in the GnomAD database, including 6,368 homozygotes. There are 18,988 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.17 ( 3067 hom., 5010 hem., cov: 22)
Exomes 𝑓: 0.039 ( 3301 hom. 13978 hem. )

Consequence

FGD1
NM_004463.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: 0.400

Publications

7 publications found
Variant links:
Genes affected
FGD1 (HGNC:3663): (FYVE, RhoGEF and PH domain containing 1) This gene encodes a protein that contains Dbl (DH) and pleckstrin (PH) homology domains and is similar to the Rho family of small GTP-binding proteins. The encoded protein specifically binds to the Rho family GTPase Cdc42Hs and can stimulate the GDP-GTP exchange of the isoprenylated form of Cdc42Hs. It also stimulates the mitogen activated protein kinase cascade leading to c-Jun kinase SAPK/JNK1 activation. Defects in this gene are the cause of the faciogenital dysplasia in Aarskog-Scott syndrome and a syndromatic form of X-linked cognitive disability. [provided by RefSeq, Jul 2017]
FGD1 Gene-Disease associations (from GenCC):
  • Aarskog-Scott syndrome, X-linked
    Inheritance: AD, XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P, ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.63).
BP6
Variant X-54449716-A-G is Benign according to our data. Variant chrX-54449716-A-G is described in ClinVar as Benign. ClinVar VariationId is 95086.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.4 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.508 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
FGD1NM_004463.3 linkc.2091T>C p.Thr697Thr synonymous_variant Exon 14 of 18 ENST00000375135.4 NP_004454.2 P98174A0A024R9Y5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
FGD1ENST00000375135.4 linkc.2091T>C p.Thr697Thr synonymous_variant Exon 14 of 18 1 NM_004463.3 ENSP00000364277.3 P98174

Frequencies

GnomAD3 genomes
AF:
0.166
AC:
18294
AN:
110312
Hom.:
3064
Cov.:
22
show subpopulations
Gnomad AFR
AF:
0.515
Gnomad AMI
AF:
0.00587
Gnomad AMR
AF:
0.0781
Gnomad ASJ
AF:
0.0155
Gnomad EAS
AF:
0.0982
Gnomad SAS
AF:
0.105
Gnomad FIN
AF:
0.0252
Gnomad MID
AF:
0.0759
Gnomad NFE
AF:
0.0192
Gnomad OTH
AF:
0.137
GnomAD2 exomes
AF:
0.0743
AC:
13586
AN:
182735
AF XY:
0.0644
show subpopulations
Gnomad AFR exome
AF:
0.529
Gnomad AMR exome
AF:
0.0398
Gnomad ASJ exome
AF:
0.0157
Gnomad EAS exome
AF:
0.0964
Gnomad FIN exome
AF:
0.0288
Gnomad NFE exome
AF:
0.0187
Gnomad OTH exome
AF:
0.0485
GnomAD4 exome
AF:
0.0391
AC:
42812
AN:
1096173
Hom.:
3301
Cov.:
29
AF XY:
0.0386
AC XY:
13978
AN XY:
361799
show subpopulations
African (AFR)
AF:
0.526
AC:
13811
AN:
26266
American (AMR)
AF:
0.0443
AC:
1559
AN:
35178
Ashkenazi Jewish (ASJ)
AF:
0.0189
AC:
367
AN:
19370
East Asian (EAS)
AF:
0.0894
AC:
2698
AN:
30188
South Asian (SAS)
AF:
0.0968
AC:
5232
AN:
54065
European-Finnish (FIN)
AF:
0.0278
AC:
1126
AN:
40530
Middle Eastern (MID)
AF:
0.0646
AC:
266
AN:
4119
European-Non Finnish (NFE)
AF:
0.0173
AC:
14504
AN:
840440
Other (OTH)
AF:
0.0706
AC:
3249
AN:
46017
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.450
Heterozygous variant carriers
0
1109
2219
3328
4438
5547
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
844
1688
2532
3376
4220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.166
AC:
18323
AN:
110368
Hom.:
3067
Cov.:
22
AF XY:
0.154
AC XY:
5010
AN XY:
32630
show subpopulations
African (AFR)
AF:
0.514
AC:
15473
AN:
30084
American (AMR)
AF:
0.0780
AC:
806
AN:
10338
Ashkenazi Jewish (ASJ)
AF:
0.0155
AC:
41
AN:
2638
East Asian (EAS)
AF:
0.0979
AC:
340
AN:
3472
South Asian (SAS)
AF:
0.104
AC:
269
AN:
2577
European-Finnish (FIN)
AF:
0.0252
AC:
151
AN:
5987
Middle Eastern (MID)
AF:
0.0783
AC:
17
AN:
217
European-Non Finnish (NFE)
AF:
0.0192
AC:
1013
AN:
52872
Other (OTH)
AF:
0.139
AC:
209
AN:
1501
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
360
719
1079
1438
1798
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
168
336
504
672
840
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0726
Hom.:
4328
Bravo
AF:
0.188
EpiCase
AF:
0.0229
EpiControl
AF:
0.0225

ClinVar

Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 16, 2012
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 28, 2018
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

p.Thr697Thr in exon 14 of FGD1: This variant is not expected to have clinical significance because it does not alter an amino acid residue, is not located within the splice consensus sequence, and has been identified in 52.77% (4481/8491) of African chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs12011120). -

not provided Benign:3
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 04, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Inborn genetic diseases Benign:1
Jul 12, 2015
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.63
CADD
Benign
7.4
DANN
Benign
0.76
PhyloP100
0.40
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs12011120; hg19: chrX-54476149; COSMIC: COSV64308593; COSMIC: COSV64308593; API